Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics to $31 from $27 and keeps an Overweight rating on the shares. The company’s Q2 EPS and revenue both beat expectations and management raised its FY23 revenue guidance, the analyst tells investors. Looking ahead, data from the Phase III GRACE trial should be released, which is relatively low-risk and will help enable the company to widen its CS franchise patient footprint over time, the firm says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept Therapeutics price target raised to $47.50 from $44 at Ladenburg
- Corcept Therapeutics price target raised to $32 from $30 at H.C. Wainwright
- Corcept Therapeutics reports Q2 EPS 25c, consensus 15c
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
- CORT Upcoming Earnings Report: What to Expect?